But remember what the World Health Organization said about the pharmaceutical industry spending far more on marketing than it does on research and development? Thanks to an aggressive and short-sighted direct-to-consumer marketing push, which prompts consumers to “ask your doctor” about any given ailment (in this case, suspected low testosterone), many of the three million prescriptions written in 2012 were dispensed to inappropriate candidates for these drugs. Suspiciously enough, the demand for testosterone-increasing products has tripled since 2001, and in 2012, testosterone drugs alone raked in roughly two billion dollars for Big Pharma.
Primary hypogonadism (congenital or acquired): Testicular failure due to diseases and conditions in the body such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter Syndrome, chemotherapy, or toxic damage from alcohol or heavy metals; these men usually have low serum testosterone levels and gonadotropins (FSH, LH) above normal range Hypogonadotropic hypogonadism (congenital or acquired): Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation; these men have low testosterone serum concentrations but have gonadotropins in the normal or low range.
The most troublesome potential risk of raising testosterone levels, and this relates primarily to medical replacement therapy, is that a silent prostate cancer may be “fed and unmasked” by supplying outside testosterone. Other risks include worsening of cholesterol, increased red blood cell counts and enlargement of the prostate. The connection between prostate issues and testosterone replacement therapy is not overly clear, and different research studies often yield conflicting results. Again, it is important to weight risks versus benefits when deciding on testosterone replacement therapy.